Filter

Refine by collections

  • Hormones and Cancer (16)

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 16 items for :

  • 5-year risk x
  • Hormones and Cancer x
Clear All
Peiwen Wu Department of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Search for other papers by Peiwen Wu in
Google Scholar
PubMed Close
,
Dongjie He Department of Radiation Oncology, Tangdu Hospital, the Second Affiliated Hospital of Air Force Medical University, Xi’an, China

Search for other papers by Dongjie He in
Google Scholar
PubMed Close
,
Hao Chang Department of Radiation Oncology, Tangdu Hospital, the Second Affiliated Hospital of Air Force Medical University, Xi’an, China

Search for other papers by Hao Chang in
Google Scholar
PubMed Close
, and
Xiaozhi Zhang Department of Radiation Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Search for other papers by Xiaozhi Zhang in
Google Scholar
PubMed Close

those of G4 disease (5-year: AAPC, 0.54; 95% CI, 0.14–0.94; 10-year: AAPC, 0.32; 95% CI, −0.62–1.28). Multivariable analysis of OS Next, we performed a multivariate analysis to further explore the independent prognostic risk factors ( Fig. 6

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-23-0331
Volume/Issue:
Volume 12: Issue 12
Open access
Luca Giovanella Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland

Search for other papers by Luca Giovanella in
Google Scholar
PubMed Close
,
Maria Luisa Garo Mathsly Research, Brescia and Vibo Valentia, Italy

Search for other papers by Maria Luisa Garo in
Google Scholar
PubMed Close
,
Domenico Albano Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy

Search for other papers by Domenico Albano in
Google Scholar
PubMed Close
,
Rainer Görges Department of Nuclear Medicine, University Hospital of Essen, Essen, Germany

Search for other papers by Rainer Görges in
Google Scholar
PubMed Close
, and
Luca Ceriani Clinic for Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
Faculty of Biomedical Sciences, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland

Search for other papers by Luca Ceriani in
Google Scholar
PubMed Close

  = 127) (2.38 (95% CI: 1.71; 3.30; test of 𝜗: z = 5.16, P   < 0.001; test of homogeneity: Q = 𝜒 2 (4) = 2.49, P   = 0.65; I 2  = 0.00%) ( Fig. 5 ). Risk ratio of patients with Tg-DT < 1 year showed no significantly changes after subgroup analysis

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0648
Volume/Issue:
Volume 11: Issue 4
Open access
Jiaxin Luo Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Jiaxin Luo in
Google Scholar
PubMed Close
,
Weili Yin Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Weili Yin in
Google Scholar
PubMed Close
,
Qiuxia Lin The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Qiuxia Lin in
Google Scholar
PubMed Close
,
Juqing Wu Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Juqing Wu in
Google Scholar
PubMed Close
,
Pan Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Pan Chen in
Google Scholar
PubMed Close
,
Yuanna Ling Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Yuanna Ling in
Google Scholar
PubMed Close
,
Jing Wang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Jing Wang in
Google Scholar
PubMed Close
,
Zhen Li Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Zhen Li in
Google Scholar
PubMed Close
,
Liqin Pan Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Liqin Pan in
Google Scholar
PubMed Close
,
Yanying Chen Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Yanying Chen in
Google Scholar
PubMed Close
,
Wei Ouyang Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Wei Ouyang in
Google Scholar
PubMed Close
, and
Huijuan Feng Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, China

Search for other papers by Huijuan Feng in
Google Scholar
PubMed Close

.602–83.398 months), and the 3- and 5-year LPFS probabilities were 57.8 and 45.1%, respectively ( Fig. 2 ). Log-rank analysis ( Fig. 3 and Table 5 ) showed that the impacts of the following six variables on LPFS were statistically significant: bone metastasis as

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0042
Volume/Issue:
Volume 11: Issue 3
Open access
Nikolaos Kyriakakis Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed Close
,
Marilena Giannoudi Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed Close
,
Satish S Kumar Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Satish S Kumar in
Google Scholar
PubMed Close
,
Khyatisha Seejore Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Khyatisha Seejore in
Google Scholar
PubMed Close
,
Georgios K Dimitriadis Department of Endocrinology, King’s College Hospital NHS Foundation Trust, Denmark Hill, London, UK

Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed Close
,
Harpal Randeva Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK

Search for other papers by Harpal Randeva in
Google Scholar
PubMed Close
,
Adam Glaser Pediatric Oncology, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute of Medical Research, University of Leeds, UK

Search for other papers by Adam Glaser in
Google Scholar
PubMed Close
,
Michelle Kwok-Williams Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed Close
,
Georgina Gerrard Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Georgina Gerrard in
Google Scholar
PubMed Close
,
Carmel Loughrey Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Carmel Loughrey in
Google Scholar
PubMed Close
,
Ahmed Al-Qaissi Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Ahmed Al-Qaissi in
Google Scholar
PubMed Close
,
Ramzi Ajjan Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Ramzi Ajjan in
Google Scholar
PubMed Close
,
Julie Lynch Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Search for other papers by Julie Lynch in
Google Scholar
PubMed Close
, and
Robert D Murray Department of Endocrinology, Leeds Centre for Diabetes & Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK

Search for other papers by Robert D Murray in
Google Scholar
PubMed Close

malignant brain tumours before the age of 15 years ( 1 ). Not dissimilar outcomes are observed in teenage and young adults (15–40 years), in whom 5-year survival approaches 68%. In contrast, considerably lower 5-year survival rates of up to 20% are observed

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0491
Volume/Issue:
Volume 12: Issue 8
Open access
Josephina G Kuiper PHARMO Institute for Drug Outcomes Research, AE Utrecht, Netherlands
Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands

Search for other papers by Josephina G Kuiper in
Google Scholar
PubMed Close
,
Aline C Fenneman Department of Clinical and Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences (ACS), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Search for other papers by Aline C Fenneman in
Google Scholar
PubMed Close
,
Anne H van der Spek Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Search for other papers by Anne H van der Spek in
Google Scholar
PubMed Close
,
Elena Rampanelli Department of Clinical and Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences (ACS), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Search for other papers by Elena Rampanelli in
Google Scholar
PubMed Close
,
Max Nieuwdorp Department of Clinical and Experimental Vascular Medicine, Amsterdam Cardiovascular Sciences (ACS), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Search for other papers by Max Nieuwdorp in
Google Scholar
PubMed Close
,
Myrthe P P van Herk-Sukel Department of Internal Medicine and Dermatology, University Medical Center Utrecht, Utrecht, Netherlands

Search for other papers by Myrthe P P van Herk-Sukel in
Google Scholar
PubMed Close
,
Valery E P P Lemmens Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands

Search for other papers by Valery E P P Lemmens in
Google Scholar
PubMed Close
,
Ernst J Kuipers Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands

Search for other papers by Ernst J Kuipers in
Google Scholar
PubMed Close
,
Ron M C Herings PHARMO Institute for Drug Outcomes Research, AE Utrecht, Netherlands
Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, Netherlands

Search for other papers by Ron M C Herings in
Google Scholar
PubMed Close
, and
Eric Fliers Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Search for other papers by Eric Fliers in
Google Scholar
PubMed Close

, and differentiation ( 3 ). Alterations in TH bioavailability have been implicated in the development of several forms of cancer, including basal cell carcinomas ( 4 ), lung cancer ( 5 , 6 ), and colorectal cancer (CRC) ( 7 ). CRC is one of the world

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0463
Volume/Issue:
Volume 11: Issue 1
Open access
J Gebauer Department of Internal Medicine I, University Hospital of Schleswig-Holstein, Campus Luebeck and Institute for Endocrinology and Diabetes, University of Luebeck, Luebeck, Germany

Search for other papers by J Gebauer in
Google Scholar
PubMed Close
,
R Skinner Department of Paediatric and Adolescent Haematology and Oncology and Children’s BMT Unit, Great North Children’s Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK

Search for other papers by R Skinner in
Google Scholar
PubMed Close
,
R Haupt DOPO Clinic, Department of Hematology/Oncolgy, IRCCS Istituto Giannina Gaslini, Genova, Italy

Search for other papers by R Haupt in
Google Scholar
PubMed Close
,
L Kremer Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Amsterdam UMC, Emma’s Children’s Hospital, Amsterdam, The Netherlands

Search for other papers by L Kremer in
Google Scholar
PubMed Close
,
H van der Pal Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Search for other papers by H van der Pal in
Google Scholar
PubMed Close
,
G Michel Department of Health Sciences and Medicine, University of Lucerne, Luzern, Switzerland

Search for other papers by G Michel in
Google Scholar
PubMed Close
,
G T Armstrong Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA

Search for other papers by G T Armstrong in
Google Scholar
PubMed Close
,
M M Hudson Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA

Search for other papers by M M Hudson in
Google Scholar
PubMed Close
,
L Hjorth Department of Clinical Sciences Lund, Paediatrics, Lund University, Skane University Hospital, Lund, Sweden

Search for other papers by L Hjorth in
Google Scholar
PubMed Close
,
H Lehnert Paris Lodron University of Salzburg, Salzburg, Austria

Search for other papers by H Lehnert in
Google Scholar
PubMed Close
, and
T Langer Pediatric Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany

Search for other papers by T Langer in
Google Scholar
PubMed Close

. Figure 1 Changes in 5-year relative survival (in %, y-axis) for childhood cancer patients (age: 0–14 years) with different cancer entities (x-axis) between 1975 and 2012 (data from ( 1 )). Despite the advances in cancer treatment, many long

Article Type:
Review Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0083
Volume/Issue:
Volume 11: Issue 9
Open access
Judith Gebauer Department of Internal Medicine I, University Hospital Schleswig-Holstein, Luebeck, Germany

Search for other papers by Judith Gebauer in
Google Scholar
PubMed Close
and
Claire E Higham Department of Endocrinology, Christie Hospital NHS Foundation Trust, University of Manchester, and Manchester Academic Health Science Centre, Manchester, UK

Search for other papers by Claire E Higham in
Google Scholar
PubMed Close

In 2020, there were 19.3 million new cancer cases diagnosed globally ( 1 , 2 ), and numbers continue to rise. During the last few decades, cancer survival has improved considerably; in the 1960s, children had a 5-year cancer survival rate of

Article Type:
Editorial
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0261
Volume/Issue:
Volume 11: Issue 9
Open access
Margarida Brito Department of Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

Search for other papers by Margarida Brito in
Google Scholar
PubMed Close
,
Susana Prazeres Department of Clinical Pathology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

Search for other papers by Susana Prazeres in
Google Scholar
PubMed Close
, and
Marta Malheiros Department of Clinical Pathology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

Search for other papers by Marta Malheiros in
Google Scholar
PubMed Close

in postmenopausal patients ( 3 ). Yet, the recent positive results from the trials PALOMA 3 ( 4 ) and MONARCH 2 ( 5 ) in the ABC premenopausal groups ER+ HER2− have come to support its generalized use in these patients in association with CDK4

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-23-0178
Volume/Issue:
Volume 12: Issue 11
Open access
Carole Morin Hospices Civils de Lyon, Hôpital Edouard Herriot, Oncologie Digestive, Lyon Cedex 03, France

Search for other papers by Carole Morin in
Google Scholar
PubMed Close
,
Keo-Morakort Benedetto Hospices Civils de Lyon, Hôpital Edouard Herriot, Oncologie Digestive, Lyon Cedex 03, France

Search for other papers by Keo-Morakort Benedetto in
Google Scholar
PubMed Close
,
Agathe Deville Hospices Civils de Lyon, Hôpital Louis Pradel, Médecine Nucléaire, Bron, France
Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France

Search for other papers by Agathe Deville in
Google Scholar
PubMed Close
,
Laurent Milot Hospices Civils de Lyon, Hôpital Edouard Herriot, Radiologie, Lyon Cedex 03, France
University of Lyon, Université Lyon 1, France

Search for other papers by Laurent Milot in
Google Scholar
PubMed Close
,
Aurélie Theillaumas Hospices Civils de Lyon, Hôpital Edouard Herriot, Oncologie Digestive, Lyon Cedex 03, France

Search for other papers by Aurélie Theillaumas in
Google Scholar
PubMed Close
,
Valérie Hervieu Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France
University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Institut de Pathologie Est, Bron Cedex, France

Search for other papers by Valérie Hervieu in
Google Scholar
PubMed Close
,
Mathieu Pioche University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Hôpital Edouard Herriot, Gastroentérologie, Lyon Cedex 03, France

Search for other papers by Mathieu Pioche in
Google Scholar
PubMed Close
,
Gilles Poncet Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France
University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Hôpital Edouard Herriot, Chirurgie Digestive, Lyon Cedex 03, France

Search for other papers by Gilles Poncet in
Google Scholar
PubMed Close
,
Julien Forestier Hospices Civils de Lyon, Hôpital Edouard Herriot, Oncologie Digestive, Lyon Cedex 03, France

Search for other papers by Julien Forestier in
Google Scholar
PubMed Close
,
Laurent François Hospices Civils de Lyon, Hôpital Louis Pradel, Exploration Fonctionnelle, Bron Cedex, France

Search for other papers by Laurent François in
Google Scholar
PubMed Close
,
Francoise Borson-Chazot University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Hôpital Louis Pradel, Endocrinologie, Bron Cedex, France

Search for other papers by Francoise Borson-Chazot in
Google Scholar
PubMed Close
,
Mustapha Adham University of Lyon, Université Lyon 1, France
Hospices Civils de Lyon, Hôpital Edouard Herriot, Chirurgie Digestive, Lyon Cedex 03, France

Search for other papers by Mustapha Adham in
Google Scholar
PubMed Close
,
Catherine Lombard-Bohas Hospices Civils de Lyon, Hôpital Edouard Herriot, Oncologie Digestive, Lyon Cedex 03, France

Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed Close
, and
Thomas Walter Hospices Civils de Lyon, Hôpital Edouard Herriot, Oncologie Digestive, Lyon Cedex 03, France
Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon Cedex 08, France
University of Lyon, Université Lyon 1, France

Search for other papers by Thomas Walter in
Google Scholar
PubMed Close

.3)  Second year 304 (49.4) 83 (48.8) 221 (49.7) Median age in years (IQR) 63 (52–72) 63 (51–70) 63 (52–73) 0.21 Female, n (%) 264 (42.5) 65 (39.2) 199 (43.7) 0.60 Place of residence, n (%) 0

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0097
Volume/Issue:
Volume 11: Issue 6
Open access
Mark J C van Treijen Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Mark J C van Treijen in
Google Scholar
PubMed Close
,
Catharina M Korse Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Catharina M Korse in
Google Scholar
PubMed Close
,
Wieke H Verbeek Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Gastroenterology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Wieke H Verbeek in
Google Scholar
PubMed Close
,
Margot E T Tesselaar Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Search for other papers by Margot E T Tesselaar in
Google Scholar
PubMed Close
, and
Gerlof D Valk Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Center for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Gerlof D Valk in
Google Scholar
PubMed Close

time to progression was 24.5 (range: 0–62) months. In 12 patients, a NETest score in the year prior to PD (median time between sample and progression: 1.5 months) was available. The median NETest score was 80 (range: 13–93) with 10/12 (83%) NETest

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0146
Volume/Issue:
Volume 11: Issue 10
Open access